KR20170003651A - 항-ａｎｇ2 항체의 사용 방법 - Google Patents

항-ａｎｇ2 항체의 사용 방법 Download PDF

Info

Publication number
KR20170003651A
KR20170003651A KR1020167034326A KR20167034326A KR20170003651A KR 20170003651 A KR20170003651 A KR 20170003651A KR 1020167034326 A KR1020167034326 A KR 1020167034326A KR 20167034326 A KR20167034326 A KR 20167034326A KR 20170003651 A KR20170003651 A KR 20170003651A
Authority
KR
South Korea
Prior art keywords
antibody
functional portion
dose
administered
ang2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167034326A
Other languages
English (en)
Korean (ko)
Inventor
도미닉 라이
로버트 시코르스키
데이비드 하이만
나이에르 에이 리즈비
Original Assignee
메디뮨 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 엘엘씨 filed Critical 메디뮨 엘엘씨
Publication of KR20170003651A publication Critical patent/KR20170003651A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167034326A 2014-05-07 2015-05-06 항-ａｎｇ2 항체의 사용 방법 Ceased KR20170003651A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461989884P 2014-05-07 2014-05-07
US61/989,884 2014-05-07
US201462005525P 2014-05-30 2014-05-30
US62/005,525 2014-05-30
PCT/US2015/029447 WO2015171747A1 (en) 2014-05-07 2015-05-06 Methods of using anti-ang2 antibodies

Publications (1)

Publication Number Publication Date
KR20170003651A true KR20170003651A (ko) 2017-01-09

Family

ID=54392949

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167034326A Ceased KR20170003651A (ko) 2014-05-07 2015-05-06 항-ａｎｇ2 항체의 사용 방법

Country Status (12)

Country Link
US (1) US20170058025A1 (enExample)
EP (1) EP3139956A4 (enExample)
JP (1) JP2017514854A (enExample)
KR (1) KR20170003651A (enExample)
CN (1) CN107206067A (enExample)
AU (1) AU2015256052A1 (enExample)
CA (1) CA2946906A1 (enExample)
HK (1) HK1244445A1 (enExample)
IL (1) IL248391A0 (enExample)
RU (1) RU2016147521A (enExample)
SG (1) SG11201609168PA (enExample)
WO (1) WO2015171747A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020175886A1 (ko) * 2019-02-25 2020-09-03 주식회사 파멥신 항-ang2 항체 및 이의 용도

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
KR102543878B1 (ko) * 2016-08-23 2023-06-14 메디뮨 리미티드 항-ｖｅｇｆ-ａ 및 항-ａｎｇ2 항체 및 이의 용도
CN110996970A (zh) 2017-06-02 2020-04-10 亚利桑那州立大学董事会 创建个性化癌症疫苗的方法
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
EP3950725A4 (en) 2019-05-08 2023-07-19 Daikin Industries, Ltd. Fluoropolymer production method and fluoropolymer
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2509085C2 (ru) * 2008-01-28 2014-03-10 Медиммун Лимитед Стабилизированные антитела против ангиопоэтина-2 и их применение
US8980268B2 (en) * 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
CN110227154A (zh) * 2010-02-23 2019-09-13 霍夫曼-拉罗奇有限公司 用于治疗卵巢癌的抗血管发生疗法
CN102250247B (zh) * 2011-06-15 2013-06-19 常州亚当生物技术有限公司 一种抗vegf/ang2双特异性抗体及其应用
EP2783510A1 (en) * 2011-11-21 2014-10-01 Motorola Mobility LLC Implicit determination and combined implicit and explicit determination of collocated picture for temporal prediction
SG11201500903XA (en) * 2012-08-07 2015-03-30 Genentech Inc Combination therapy for the treatment of glioblastoma

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020175886A1 (ko) * 2019-02-25 2020-09-03 주식회사 파멥신 항-ang2 항체 및 이의 용도
CN113728004A (zh) * 2019-02-25 2021-11-30 药物抗体公司 抗Ang2抗体及其用途
JP2022522195A (ja) * 2019-02-25 2022-04-14 ファームアブシン・インコーポレイテッド 抗ａｎｇ２抗体及びその用途

Also Published As

Publication number Publication date
US20170058025A1 (en) 2017-03-02
IL248391A0 (en) 2016-11-30
CA2946906A1 (en) 2015-11-12
RU2016147521A3 (enExample) 2018-12-27
SG11201609168PA (en) 2016-12-29
CN107206067A (zh) 2017-09-26
RU2016147521A (ru) 2018-06-09
HK1244445A1 (zh) 2018-08-10
EP3139956A1 (en) 2017-03-15
EP3139956A4 (en) 2017-11-29
JP2017514854A (ja) 2017-06-08
WO2015171747A1 (en) 2015-11-12
AU2015256052A1 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
KR20170003651A (ko) 항-ａｎｇ2 항체의 사용 방법
Shimamoto et al. Peptibodies: A flexible alternative format to antibodies
Li et al. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects
JP6038650B2 (ja) Ｄｌｌ４アンタゴニスト及び化学療法剤を用いたがんの治療方法
JP2024075620A (ja) 長時間作用型ｆｇｆ２１融合タンパク質およびそれを含む医薬組成物
EP4414381A1 (en) Il-10 monomer fusion protein and use thereof
CN118662652A (zh) 核酸-多肽组合物及其用途
BR112018012641A2 (pt) molécula de penetração de célula portadora de fármaco, métodos para facilitar a incorporação de um composto biologicamente ativo (bac) em uma célula, para melhorar a biodisponibilidade de um fármaco ou bac, para introduzir um fármaco ou bac em um sítio e para alterar a expressão de um gene endógeno ou exógeno, e, composição.
US20130006034A1 (en) Methods of enhancing the response to radiation in tumor therapy using anti-dll4 antibodies
Liu et al. Targeted EpCAM-binding for the development of potent and effective anticancer proteins
CN116802303A (zh) 用于预防和治疗癌症的沙门氏菌菌株及其用途
US10744186B2 (en) Method of treating cancer with compositions comprising IL-31
KR20250099250A (ko) 비만 치료 방법
CN120344265A (zh) 单独使用双特异性EGFR x CD28抗体或其与抗PD-1抗体组合使用治疗癌症的方法
CN114191558A (zh) Egfr抑制剂与抗血管新生药物在治疗肿瘤疾病的药物中的用途
US20200255506A1 (en) Treatment of ck8 positive cancers in relation with k-ras gene status
Calfa et al. Antibodies and antibody-fusion proteins as anti-angiogenic, anti-tumor agents
KR20160075107A (ko) 페길화된 vegf 트랩 및 이의 제조방법
CN119300862A (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
KR20260008678A (ko) 아포지질단백질 및 Fc 부위 결합 펩타이드를 포함하는 융합 단백질 및 이의 용도
HK40116183A (zh) 核酸-多肽组合物及其用途
Chon et al. 1019eTiP A phase I, multi-center, open-label, dose escalation and expansion study of AST-201 in patients with GPC3-positive advanced solid tumors
JP2015536909A (ja) 合成ポリヌクレオチド結合ペプチドのファミリーおよびその使用
CN118059217A (zh) 一种表观遗传药物联合过继单核/巨噬细胞免疫治疗在制备肿瘤疾病生物药品中的应用
CN117085124A (zh) 一种包含抗PD-L1抗体和c-Met激酶抑制剂的药物组合

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161207

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200506

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211007

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211209

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211007

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I